 XProTM treatment shows statistically significant decrease in Phospho Tau 217 pT271 and pT181, and an improvement in an imaging biomarker of myelination. XProTM treatment shows statistically significant decrease in Phospho Tau 217 pT271 and pT181, and an improvement in an imaging biomarker of myelination. 